Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow (Indirect Method) | ||||||||||
| Cash from operating activities | 37.47M | 49.02M | 13.33M | |||||||
| Net profit before non-cash adjustment | ---2.87M | --8.98M | --23.71M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Total adjustment of non-cash items | --55.38M | --30.82M | --43.69M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| -Depreciation and amortization | --41.69M | --42.67M | --47.75M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| -Reversal of impairment losses recognized in profit and loss | --1.09M | ---1.24M | ---1.3M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| -Disposal profit | ---241K | ---1K | ---16K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| -Net exchange gains and losses | --7.23M | ---19.14M | ---3.34M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| -Remuneration paid in stock | --153K | --0 | --85K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| -Other non-cash items | --5.46M | --8.53M | --506K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Changes in working capital | ---15.04M | --9.21M | ---54.07M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| -Change in receivables | ---29.95M | --34.31M | ---41.57M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| -Change in inventory | ---2.96M | ---3.19M | --15.32M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| -Change in payables | --17.31M | --12.58M | ---6.66M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| -Changes in other current assets | --567K | ---34.48M | ---21.15M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Dividends paid (cash flow from operating activities) | ||||||||||
| Dividends received (cash flow from operating activities) | ||||||||||
| Interest paid (cash flow from operating activities) | ||||||||||
| Interest received (cash flow from operating activities) | ||||||||||
| Tax refund paid | -2.3M | -4.25M | -4.49M | |||||||
| Other operating cash inflow (outflow) | 0 | 0 | 0 | |||||||
| Operating cash flow | --35.17M | --44.76M | --8.84M | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Investing cash flow | ||||||||||
| Net PPE purchase and sale | -9.71%-50.15M | 39.04%-34.34M | 104.20%2.25M | 68.02%-224.7M | 2.46%-69.14M | 59.89%-45.71M | ---56.32M | ---53.53M | -166.15%-702.7M | 41.80%-70.88M |
| Net business purchase and sale | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | 99.78%-168K | --0 |
| Advance cash and loans provided to other parties | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --0 | ---- |
| Dividends received (cash flow from investment activities) | ---- | ---- | ---- | --0 | --0 | ---29K | ---- | ---- | --29K | ---- |
| Interest received (cash flow from investment activities) | -90.91%683K | -12.00%-1.84M | 75.13%5.55M | -61.35%13.09M | 53.31%4.05M | 321.24%7.52M | ---1.64M | --3.17M | 405.57%33.87M | -13.44%2.64M |
| Net changes in other investments | ---- | ---- | ---- | --30.77M | ---- | ---- | ---- | ---- | ---- | ---- |
| Investing cash flow | -35.30%-51.71M | 37.56%-36.18M | 115.48%7.8M | 72.97%-180.84M | 49.71%-34.32M | 65.93%-38.22M | ---57.94M | ---50.36M | -99.98%-668.97M | 42.49%-68.24M |
| Financing cash flow | ||||||||||
| Net issuance payments of debt | 89.93%-20.13M | -369.43%-28.1M | 101.49%999K | -399.50%-184.13M | 2,606.87%72.46M | -1,251.42%-199.78M | --10.43M | ---67.24M | -146.30%-36.86M | 136.92%2.68M |
| Net common stock issuance | --819K | ---- | ---- | 194,806.90%113.05M | ---3.85M | --0 | ---- | ---- | -99.97%58K | --0 |
| Increase or decrease of lease financing | 10.00%-36K | -175.00%-55K | 65.00%-14K | 20.00%-1.92M | -6,640.74%-1.82M | -48.15%-40K | ---20K | ---40K | -78.31%-2.4M | 97.88%-27K |
| Cash dividends for minorities | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | ---35K | ---- |
| Interest paid (cash flow from financing activities) | -158.85%-1.19M | -33.75%-1.94M | 91.31%-1.36M | 28.99%-33.82M | -141.55%-18.75M | 130.33%2.03M | ---1.45M | ---15.64M | -37.56%-47.63M | 48.22%-7.76M |
| Net other fund-raising expenses | 41.39%87.97M | 21.22%-14.19M | 12.12%-8.96M | 141.31%14.26M | 51.98%-19.76M | 370.89%62.22M | ---18.01M | ---10.19M | 80.25%-34.51M | -554.79%-41.15M |
| Financing cash flow | 149.74%67.43M | -141.07%-44.29M | 89.98%-9.33M | 23.74%-92.57M | 161.14%28.29M | -204.90%-135.58M | --107.84M | ---93.11M | -254.36%-121.37M | 4.31%-46.26M |
| Net cash flow | ||||||||||
| Beginning cash position | -50.88%177.28M | -26.51%200.22M | -40.44%191.8M | -53.87%322.01M | -65.28%162.39M | -37.03%360.91M | --272.45M | --322.01M | 176.51%698.06M | -36.73%467.73M |
| Current changes in cash | 133.45%50.89M | -147.07%-35.71M | 111.47%7.31M | 70.59%-121.11M | 116.99%18.85M | -43.98%-152.15M | --75.86M | ---63.67M | -211.01%-411.75M | -21.55%-110.95M |
| Effect of exchange rate changes | 54.84%-20.94M | 1.40%12.77M | -92.08%1.12M | -125.50%-9.11M | 43.43%10.56M | -20,000.86%-46.37M | --12.6M | --14.11M | -52.19%35.71M | -85.28%7.36M |
| End cash Position | 27.62%207.23M | -50.88%177.28M | -26.51%200.22M | -40.44%191.8M | -47.33%191.8M | -65.28%162.39M | --360.91M | --272.45M | -53.87%322.01M | -47.83%364.15M |
| Free cash flow | 37.82%-14.98M | 134.35%10.43M | -228.17%-33.68M | 77.32%-73.7M | 32.40%-45.52M | 61.76%-24.09M | ---30.36M | --26.27M | -190.08%-324.95M | -39.89%-67.34M |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.